WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 314203
CAS#: 842133-18-0 (free)
Description: Canagliflozin (INN, trade name Invokana) is a drug for the treatment of type 2 diabetes. It was developed by Mitsubishi Tanabe Pharma and is marketed under license by Janssen, a division of Johnson & Johnson. Canagliflozin is an inhibitor of subtype 2 sodium-glucose transport protein (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the urine. In March 2013, canagliflozin became the first SGLT2 inhibitor to be approved in the United States.
MedKoo Cat#: 314203
Name: Canagliflozin
CAS#: 842133-18-0 (free)
Chemical Formula: C24H25FO5S
Exact Mass: 444.14067
Molecular Weight: 444.52
Elemental Analysis: C, 64.85; H, 5.67; F, 4.27; O, 18.00; S, 7.21
Related CAS #: 928672-86-0 (hemihydrate) 842133-18-0 (free)
Synonym: JNJ 24831754; INJ24831754; JNJ-24831754; JNJ24831754AAA; JNJ24831754ZAE; TA 7284; TA-7284; TA7284; Canagliflozin; Trade name: Invokana.
IUPAC/Chemical Name: (3R,4R,5S,6R)-2-(3-((5-(4-fluorophenyl)thiophen-2-yl)methyl)-4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
InChi Key: XTNGUQKDFGDXSJ-KKEQRHKBSA-N
InChi Code: InChI=1S/C24H25FO5S/c1-13-2-3-15(24-23(29)22(28)21(27)19(12-26)30-24)10-16(13)11-18-8-9-20(31-18)14-4-6-17(25)7-5-14/h2-10,19,21-24,26-29H,11-12H2,1H3/t19-,21-,22+,23-,24?/m1/s1
SMILES Code: O[C@H]1C(C2=CC=C(C)C(CC3=CC=C(C4=CC=C(F)C=C4)S3)=C2)O[C@H](CO)[C@@H](O)[C@@H]1O
Appearance: white solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO.
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 444.52 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Davidson JA, Sloan L. Fixed-Dose Combination of Canagliflozin and Metformin for the Treatment of Type 2 Diabetes: An Overview. Adv Ther. 2016 Nov 16. [Epub ahead of print] Review. PubMed PMID: 27854055.
2: Qiu R, Balis D, Capuano G, Xie J, Meininger G. Canagliflozin: Efficacy and Safety in Combination with Metformin Alone or with Other Antihyperglycemic Agents in Type 2 Diabetes. Diabetes Ther. 2016 Oct 12. [Epub ahead of print] Review. PubMed PMID: 27734320.
3: Canagliflozin (Invokana) for Type 2 Diabetes Mellitus [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Sep. Available from http://www.ncbi.nlm.nih.gov/books/NBK349575/ PubMed PMID: 26962611.
4: Kaur K, Likar N, Dang A, Kaur G. Efficacy and safety of canagliflozin among patients with type 2 diabetes mellitus: A systematic review and meta-analysis. Indian J Endocrinol Metab. 2015 Nov-Dec;19(6):705-21. doi: 10.4103/2230-8210.167562. Review. PubMed PMID: 26693420; PubMed Central PMCID: PMC4673798.
5: Parveen R, Agarwal NB, Kaushal N, Mali G, Raisuddin S. Efficacy and safety of canagliflozin in type 2 diabetes mellitus: systematic review of randomized controlled trials. Expert Opin Pharmacother. 2016;17(1):105-15. doi: 10.1517/14656566.2016.1109629. Review. PubMed PMID: 26650511.
6: Seufert J. SGLT2 inhibitors - an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin. Diabetes Metab Syndr Obes. 2015 Nov 9;8:543-54. doi: 10.2147/DMSO.S90662. Review. PubMed PMID: 26609242; PubMed Central PMCID: PMC4644173.
7: Syed SH, Gosavi S, Shami W, Bustamante M, Farah Z, Teleb M, Abbas A, Said S, Mukherjee D. A Review of Sodium Glucose Co-transporter 2 Inhibitors Canagliflozin, Dapagliflozin and Empagliflozin. Cardiovasc Hematol Agents Med Chem. 2015;13(2):105-12. Review. PubMed PMID: 26549321.
8: Triplitt C, Cornell S. Canagliflozin Treatment in Patients with Type 2 Diabetes Mellitus. Clin Med Insights Endocrinol Diabetes. 2015 Oct 18;8:73-81. doi: 10.4137/CMED.S31526. Review. PubMed PMID: 26523120; PubMed Central PMCID: PMC4610726.
9: Perkovic V, Jardine M, Vijapurkar U, Meininger G. Renal effects of canagliflozin in type 2 diabetes mellitus. Curr Med Res Opin. 2015 Dec;31(12):2219-31. doi: 10.1185/03007995.2015.1092128. Review. PubMed PMID: 26494163.
10: Rosenthal N, Meininger G, Ways K, Polidori D, Desai M, Qiu R, Alba M, Vercruysse F, Balis D, Shaw W, Edwards R, Bull S, Di Prospero N, Sha S, Rothenberg P, Canovatchel W, Demarest K. Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus. Ann N Y Acad Sci. 2015 Nov;1358:28-43. doi: 10.1111/nyas.12852. Review. PubMed PMID: 26305874.
11: Fleming JW, Fleming LW, Davis CS. Fixed-dose combinations in type 2 diabetes - role of the canagliflozin metformin combination. Diabetes Metab Syndr Obes. 2015 Jun 25;8:287-94. doi: 10.2147/DMSO.S69282. Review. PubMed PMID: 26150733; PubMed Central PMCID: PMC4485795.
12: Patel S, Gohel K, Patel BG. A Systematic Review on Effect of Canagliflozin in Special Population. Curr Diabetes Rev. 2016;12(3):211-22. Review. PubMed PMID: 26084476.
13: Devineni D, Polidori D. Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor. Clin Pharmacokinet. 2015 Oct;54(10):1027-41. doi: 10.1007/s40262-015-0285-z. Review. PubMed PMID: 26041408.
14: Scheen AJ. [Canagliflozin (Invokana): kidney SGLT2 cotransporter inhibitor for treating type 2 diabetes]. Rev Med Liege. 2014 Dec;69(12):692-9. Review. French. PubMed PMID: 25796788.
15: Khurana M, Vaidyanathan J, Marathe A, Mehrotra N, Sahajwalla CG, Zineh I, Jain L. Canagliflozin use in patients with renal impairment-Utility of quantitative clinical pharmacology analyses in dose optimization. J Clin Pharmacol. 2015 Jun;55(6):647-56. doi: 10.1002/jcph.466. Review. PubMed PMID: 25612234.
16: Amblee A. Patient profiling in diabetes and role of canagliflozin. Pharmgenomics Pers Med. 2014 Nov 18;7:367-77. doi: 10.2147/52761.S0. Review. PubMed PMID: 25540592; PubMed Central PMCID: PMC4270036.
17: Sehgal V, Bajwa SJ, Sehgal R, Consalvo JA. Management of diabetes in the elderly with canagliflozin: A newer hypoglycemic drug on the horizon. J Pharmacol Pharmacother. 2014 Oct;5(4):227-31. doi: 10.4103/0976-500X.142428. Review. Erratum in: J Pharmacol Pharmacother. 2015 Jan-Mar;6(1):58. PubMed PMID: 25422561; PubMed Central PMCID: PMC4231550.
18: Boyle LD, Wilding JP. A safety evaluation of canagliflozin : a first-in-class treatment for type 2 diabetes. Expert Opin Drug Saf. 2014 Nov;13(11):1535-44. doi: 10.1517/14740338.2014.959488. Review. PubMed PMID: 25340618.
19: Brunton S, Reid TS. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, for the management of type 2 diabetes. Hosp Pract (1995). 2014 Aug;42(3):96-108. doi: 10.3810/hp.2014.08.1122. Review. PubMed PMID: 25255411.
20: Rosiak M, Grzeszczak S, Kosior DA, Postuła M. Emerging treatments in type 2 diabetes: focus on canagliflozin. Ther Clin Risk Manag. 2014 Aug 21;10:683-9. doi: 10.2147/TCRM.S39145. Review. PubMed PMID: 25187722; PubMed Central PMCID: PMC4149387.
Related CAS#
842133-18-0 (Canagliflozin)
928672-86-0 (Canagliflozin hemihydrate)
